ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Abstracts From AACR Annual Meeting

May 28, 1976

In Brief: Wynder Receives ACS Award At ASCO; Brinker to Be Honored for Public Service

May 23, 1997

NIH Reauthorization Lost In The Shuffle As Congress Adjourns; NCI Budget $1.723 Bil.

November 2, 1990

NCAB Subcommittee Approves Compromise On Changes In Organ Site Program

April 9, 1982

Faulding, NaPro In Agreement For Marketing Paclitaxel.

March 30, 2001

NIEHS Conference to Look At 21st Century Issues

April 1, 1988